The extent of microbiological testing and antibiotic de-escalation in adults with community-acquired pneumonia: a retrospective cohort study. Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001
Evaluation of moxifloxacin (MXF) as empiric antibiotic therapy of CAP outpatients: A multicenter prospective study Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012
Randomized, controlled trial of efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants Source: Eur Respir J 2006; 28: Suppl. 50, 488s Year: 2006
Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives Source: Eur Respir J 2004; 24: Suppl. 48, 185s Year: 2004
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005
Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial Source: Eur Respir J, 58 (2) 2002535; 10.1183/13993003.02535-2020 Year: 2021
The impact of hyperglycemia on community-acquired pneumonia: A retrospective cohort study Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016
Efficacy and safety of stepwise therapy in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 377s Year: 2006
First data about the efficacy of moxifloxacin in the treatment of pulmonary tuberculosis – a prospective, randomised study versus INH Source: Annual Congress 2003 - Management of tuberculosis and tubercular infection - old and new considerations Year: 2003
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003
Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 674s Year: 2007
Pivot trial A multicentre randomised controlled equivalence trial comparing oral amoxycillin and intravenous penicillin for community acquired pneumonia in children Source: Eur Respir J 2004; 24: Suppl. 48, 714s Year: 2004
Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020
Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study Source: Eur Respir J 2015; 46: 1205-1207 Year: 2015
A randomized, controlled, open-label study to evaluate the efficacy and safety of oral lopinavir-ritonavir in adults hospitalized with COVID-19 virus infection Source: Virtual Congress 2020 – Chinese programme 2020: Part I Year: 2020
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study Source: Eur Respir J, 54 (1) 1900057; 10.1183/13993003.00057-2019 Year: 2019
GRACE-01 Genomics to combat resistance against antibiotics in community-acquired LRTI in Europe – a multicentre, observational cohort study of cough/LRTI in primary care Source: Annual Congress 2007 - Clinical trial: antibiotic use in the community Year: 2007
Clinical efficacy of sitafloxacin for refractory non-tuberculous mycobacterial lung disease: A single-center retrospective study Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011